IGF2BP2 plays a critical role in glioma progression, and knockdown of IGF2BP2 leads to cell autophagy, TMZ resensitization, and tumor suppression, making it a potential novel therapeutic target for glioma. Here, IGF2BP2 is linked to central nervous system cancer.